Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies

Frontiers in Immunology

Immunology

Xin Luo¹  Bixiang Zhang¹  Ze-yang Ding¹  Xiao-ping Chen¹  Wan-guang Zhang¹  Han Gao¹  Rui-zhi Chang¹ 

[1] Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China;Clinical Medicine Research Center for Hepatic Surgery of Hubei Province, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China;Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China;

关键词: hepatocellular carcinoma;    asymptomatic hyperamylasemia;    PD-1 inhibitor;    CTLA-4 inhibitor;    combined immunotherapy;   

DOI  :  10.3389/fimmu.2023.1274449

 received in 2023-08-08, accepted in 2023-09-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundCombined immunotherapy has shown promising results in the treatment of advanced HCC, whereas the priority population that would respond to the combined immunotherapy is still elusive. In addition, HCC with asymptomatic hyperamylasemia was not reported previously.Case presentationAn aged patient was diagnosed as HCC with BCLC stage C (bone metastasis). Notably, this patient showed asymptomatic hyperamylasemia. The patient was then enrolled in a trial evaluating combined immunotherapy of anti-PD-1 antibody sintilimab (IBI308) plus anti-CTLA-4 antibody (IBI310) in advanced HCC. After being treated with combined immunotherapy, this patient rapidly achieved complete response (CR) according to mRECIST criteria or immune partial response (iPR) according to iRECIST criteria and maintain the CR state for more than 12 months. Interestingly, serum levels of amylase and lipase in this patient were reduced after treatment.ConclusionWe reported, for the first time, a case of metastatic HCC with asymptomatic hyperamylasemia, and suggested that HCC patients with asymptomatic hyperamylasemia may benefit from combined immunotherapy of anti-CTLA-4 and PD-1 antibodies.

【 授权许可】

Unknown   
Copyright © 2023 Gao, Chang, Chen, Zhang, Zhang, Luo and Ding